The civic record
Read. Follow. Verify.The Medicaid VBPs for Patients Act (MVP Act)
Last action · March 9, 2026: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.Sponsors: Brett Guthrie and 17 others
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Would Do
The MVP Act proposes changes to how Medicaid and Medicare handle '' arrangements for prescription drugs. These arrangements tie the price of a drug to how well it works for a patient, and the bill aims to clarify how these prices are reported and calculated to encourage their use.
This bill changes how drug manufacturers report prices for Medicaid and Medicare, potentially altering the costs and availability of certain high-cost drugs that are paid for based on patient health outcomes.
Who It Would Affect
Groups the bill's text would affect if enacted, as described in the record. Being affected is not a position for or against it.
Medicaid beneficiaries
Patients may have different access to drugs covered under value-based purchasing arrangements.
Drug manufacturers
Companies must follow new reporting requirements for drug prices and outcome-based rebates.
State Medicaid agencies
Agencies will receive federal guidance on implementing value-based purchasing for inpatient drugs and multi-state agreements.
Key Facts
- Allows drug manufacturers to report multiple 'best price' points for a single drug if they offer a value-based purchasing arrangement to all states.
- Defines value-based purchasing arrangements as those where refunds, rebates, or price reductions occur if a patient fails to achieve specific health outcomes.
- Requires the Secretary of Health and Human Services to implement new price reporting rules via rulemaking within 180 days of enactment.
- Mandates that for drugs paid in installments, the total price must be calculated as if the full amount were paid in the first installment for rebate purposes.
Show all 8 facts
- Excludes certain value-based rebates from the calculation of a manufacturer's average sales price under Medicare.
- Requires the Secretary of Health and Human Services to issue guidance to states within 180 days on using value-based arrangements for inpatient hospital drugs.
- Provides guidance for multi-state agreements that allow for the transfer of funds so patients can receive drugs in a state other than their state of residence.
- Creates an exception to the Anti-Kickback Statute for payments made by manufacturers to states under value-based purchasing arrangements when patient outcomes are not met.
Frequently Asked Questions
What is a 'value-based purchasing arrangement'?
How does this affect my Medicaid coverage?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Currently in committee. The next step in the legislative lifecycle is Floor Vote.
Procedural history
2 actions- Mar 9, 2026HouseCommitteeReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Mar 9, 2026HouseIntroducedIntroduced in House
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Show 13 more sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Standardizing Outcome-Based Pricing
The bill represents a formal effort to codify and standardize outcome-based drug pricing, which has previously been handled through varied state-level waivers.
Connected Entities
Sources
www.congress.gov
Analysis Score
0–100- Significance65How much this matters to a regular citizen
- Controversy20Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz15Current news / social attention level
Publisher tools